$CNSP
CNS Pharmaceuticals, Inc.

2023 Q2 Form 10-Q Financial Statement

#000168316823003311 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $1.359M $1.260M
YoY Change -12.15% 7.8% -9.97%
% of Gross Profit
Research & Development $2.846M $3.568M $1.521M
YoY Change 28.1% 134.51% -31.16%
% of Gross Profit
Depreciation & Amortization $1.000K $1.279K $3.380K
YoY Change -68.75% -62.16%
% of Gross Profit
Operating Expenses $4.025M $4.927M $2.782M
YoY Change 12.93% 77.1% -22.94%
Operating Profit -$4.025M -$4.927M -$3.149M
YoY Change 12.93% 56.44%
Interest Expense $3.650K $5.436K -$2.570K
YoY Change 126.57% -311.52%
% of Operating Profit
Other Income/Expense, Net $4.152K -$5.436K -$2.566K
YoY Change -357.73% 111.85%
Pretax Income -$4.021M -$4.932M -$2.784M
YoY Change 12.77% 77.13% -22.87%
Income Tax
% Of Pretax Income
Net Earnings -$4.021M -$4.932M -$2.784M
YoY Change 12.77% 77.13% -22.94%
Net Earnings / Revenue
Basic Earnings Per Share -$1.04 -$2.59 -$2.44
Diluted Earnings Per Share -$1.04 -$2.59 -$71.75K
COMMON SHARES
Basic Shares Outstanding 4.143M shares 2.226M shares 1.294M shares
Diluted Shares Outstanding 3.877M shares 1.906M shares 1.294M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.279M $5.111M $12.44M
YoY Change -52.23% -58.92% 12.28%
Cash & Equivalents $4.279M $5.111M $12.44M
Short-Term Investments
Other Short-Term Assets $1.792M $1.862M $2.293M
YoY Change -26.52% -18.8% 45.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.071M $6.972M $14.73M
YoY Change -46.73% -52.68% 15.19%
LONG-TERM ASSETS
Property, Plant & Equipment $3.382K $4.385K $12.73K
YoY Change -69.17% -65.55% -36.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $377.2K $438.1K $1.126M
YoY Change -63.69% -61.09% 241.2%
Total Long-Term Assets $380.6K $442.5K $1.139M
YoY Change -63.75% -61.14% 225.34%
TOTAL ASSETS
Total Short-Term Assets $6.071M $6.972M $14.73M
Total Long-Term Assets $380.6K $442.5K $1.139M
Total Assets $6.452M $7.415M $15.87M
YoY Change -48.17% -53.28% 20.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.571M $2.781M $489.7K
YoY Change 627.39% 467.79% -53.8%
Accrued Expenses $260.1K $853.2K $307.0K
YoY Change -5.94% 177.92% -42.07%
Deferred Revenue
YoY Change
Short-Term Debt $166.4K $289.1K $272.6K
YoY Change 6.39% 6.06% -12.07%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.997M $3.923M $1.069M
YoY Change 332.66% 266.87% -43.72%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.997M $3.923M $1.069M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.997M $3.923M $1.069M
YoY Change 332.66% 266.87% -43.72%
SHAREHOLDERS EQUITY
Retained Earnings -$59.67M -$55.65M
YoY Change 44.36%
Common Stock $4.141K $2.226K
YoY Change -89.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.454M $3.492M $14.80M
YoY Change
Total Liabilities & Shareholders Equity $6.452M $7.415M $15.87M
YoY Change -48.17% -53.28% 20.79%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$4.021M -$4.932M -$2.784M
YoY Change 12.77% 77.13% -22.94%
Depreciation, Depletion And Amortization $1.000K $1.279K $3.380K
YoY Change -68.75% -62.16%
Cash From Operating Activities -$3.403M -$4.825M -$3.077M
YoY Change 1.2% 56.79% -7.03%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.571M -$120.3K 10.51M
YoY Change -2313.55% -101.14% 2903.77%
NET CHANGE
Cash From Operating Activities -3.403M -$4.825M -3.077M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 2.571M -$120.3K 10.51M
Net Change In Cash -831.3K -$4.945M 7.436M
YoY Change -76.12% -166.5% -351.22%
FREE CASH FLOW
Cash From Operating Activities -$3.403M -$4.825M -$3.077M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.403M -$3.077M
YoY Change 1.28% -7.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
CNS Pharmaceuticals, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2318545
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 West Loop South
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 900
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39126
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001729427
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
CY2023Q1 dei City Area Code
CityAreaCode
800
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
946-9185
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
CNSP
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4143339 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5110531 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10055407 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1861691 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2509238 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
6972222 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12564645 usd
CY2023Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
438131 usd
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
482806 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4385 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5664 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
442516 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
488470 usd
CY2023Q1 us-gaap Assets
Assets
7414738 usd
CY2022Q4 us-gaap Assets
Assets
13053115 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2780604 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3681900 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
853228 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
828391 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
289075 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3922907 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4920259 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3922907 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4920259 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2226325 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2226325 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1617325 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1617325 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2226 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1617 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
59137229 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
58846916 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55647624 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50715677 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3491831 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7414738 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13053115 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1358752 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1260409 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3567759 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1888803 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
4926511 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3149212 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4926511 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3149212 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
5436 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
2566 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5436 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2566 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3151778 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.59
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.44
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.59
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.44
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1906494 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1293612 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1906494 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1293612 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8132856 usd
CY2023Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
609 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
290313 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3491831 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6163197 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10625786 usd
CY2022Q1 CNSP Stock Issued For Exercise Of Warrants
StockIssuedForExerciseOfWarrants
2616 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
336685 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3151778 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13976506 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4931947 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3151778 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
290313 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
336685 usd
CY2023Q1 us-gaap Depreciation
Depreciation
1279 usd
CY2022Q1 us-gaap Depreciation
Depreciation
3375 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-692222 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-318124 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-901296 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-665668 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
24837 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
82063 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4824592 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3077199 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
120893 usd
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
115222 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
609 usd
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2616 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10625786 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-120284 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10513180 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4944876 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7435981 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10055407 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5004517 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5110531 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12440498 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
5436 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
2883 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_802_eus-gaap--NatureOfOperations_zeOXsrD2pae1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_822_zC8CTVuUeuZg">Nature of Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc. (“we”, “our”, the “Company”) is a clinical pharmaceutical company organized as a Nevada corporation on July 27, 2017 to focus on the development of anti-cancer drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4860531 usd
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
449874 usd
CY2022Q4 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0588 pure
CY2022Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-10-31
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
289075 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
409968 usd
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29988 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M28D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
609 usd
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
800000 usd
CY2020Q2 us-gaap Payments For Fees
PaymentsForFees
775000 usd
CY2020Q2 us-gaap Development Costs
DevelopmentCosts
1000000.0 usd

Files In Submission

Name View Source Status
0001683168-23-003311-index-headers.html Edgar Link pending
0001683168-23-003311-index.html Edgar Link pending
0001683168-23-003311.txt Edgar Link pending
0001683168-23-003311-xbrl.zip Edgar Link pending
cnsp-20230331.xsd Edgar Link pending
cns_ex3101.htm Edgar Link pending
cns_ex3102.htm Edgar Link pending
cns_ex3201.htm Edgar Link pending
cns_ex3202.htm Edgar Link pending
cns_i10q-033123.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnsp-20230331_cal.xml Edgar Link unprocessable
cnsp-20230331_pre.xml Edgar Link unprocessable
cnsp-20230331_def.xml Edgar Link unprocessable
cnsp-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cns_i10q-033123_htm.xml Edgar Link completed